xAI 的 Grok 3 模型上線，推理模式和深入研究全部免費使用！
xAI 備受期待的 Grok 3 模型稍早已正式上線，而且出乎意外地，竟然包括推理模式和深入研究等功能，全部都開放免費使用。xAI 在 X 貼文表示，Grok 3 將免費提供到「我們的伺服器融化為止」，而 X Premium+ 及 SuperGrok 的用戶則是除了能增加 Grok 3 的用量之外，也將優先取得語音模式等最新功能。
要使用 Grok 3 的話，可前往官網 grok.com，並且確定下面是選擇了「Grok 3」模型；或者是在 iOS 平台下載 Grok 的 app 使用。
與此同時，SuperGrok 訂閱服務的價位也出現在了 app 中，在美國是 US$30 的月費，或是也可以選擇年繳 US$300，實在不算便宜。在推理模式和深入研究目前都免費了的情況下，SuperGrok 的「新功能優先權」是否足以吸引用戶，就還有待觀察了。
This is it: The world's smartest AI, Grok 3, now available for free (until our servers melt).Try Grok 3 now: https://t.co/Tj0afLoxEzX Premium+ and SuperGrok users will have increased access to Grok 3, in addition to early access to advanced features like Voice Mode pic.twitter.com/YgKavSCiWr
— xAI (@xai) February 20, 2025
相關文章：
最新 Grok3 AI 模型登場：加入推理模型與 DeepSearch，Elon Musk 強調比 OpenAI、DeepSeek 更強
Grok 3 發佈後，X Preimum+ 月費即時加一倍！
緊貼最新科技資訊、網購優惠，追隨 Yahoo Tech 各大社交平台！
🎉📱 Tech Facebook：https://www.facebook.com/yahootechhk
🎉📱 Tech Instagram：https://www.instagram.com/yahootechhk/
🎉📱 Tech WhatsApp 社群：https://chat.whatsapp.com/Dg3fiiyYf3yG2mgts4Mii8
🎉📱 Tech WhatsApp 頻道：https://whatsapp.com/channel/0029Va91dmR545urVCpQwq2D
🎉📱 Tech Telegram 頻道：https://t.me/yahootechhk
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
'When He Least Expects It': Michael Cohen Warns Elon Musk Of Trump's Revenge
Michael Cohen, former longtime personal attorney to Donald Trump, on Sunday warned Elon Musk that the president isn't done with him yet. 'They're going to really go after Elon Musk like nobody has seen, ever, in this country because they can,' he said on MSNBC on Saturday. 'And one thing Elon doesn't understand is this political guerrilla warfare that they're going to conduct against him.' Cohen warned that Trump can use the power of government to target Musk's companies and even his citizenship. Musk and Trump last week had a spectacularly public falling out, and over the weekend the president slammed his one-time pal as 'very disrespectful' and warned him of 'serious consequences' if he supported Democrats. Cohen said that while Trump has also downplayed the feud, the president is likely already plotting against the billionaire behind the scenes. 'I just wish him well,' Trump said on Friday. 'No he doesn't,' Cohen said. 'Because while Elon Musk is taking a step back thinking Trump is taking a step back, what Trump is actually doing is weaponizing the Department of Justice through his attorney general and other people, and they are gonna drop the hammer on him out of nowhere when he least expects it. That's the playbook.' See more of his conversation with MSNBC's Ali Velshi below:
Yahoo
28 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Tesla Pushes Hard with New Incentives as Sales Slip
Tesla is pulling out all the stops to entice buyers as its sales continue to slide. The electric vehicle giant, long seen as the face of the EV industry, is introducing a raft of incentives and discounts to jumpstart demand. The Cool Down reported that Tesla posted its weakest sales quarter since mid-2022, prompting the company to offer discounts for various customer groups, including special deals for Lyft drivers and subsidized interest rates. Reports suggest Tesla representatives are even personally reaching out to past leads to encourage test drives. One commenter summed it up aptly: 'They're truly pulling all demand levers.' Tesla's reputation has been hit in recent years, partly due to CEO Elon Musk's polarizing political commentary, which has made the brand less appealing to some potential buyers. However, improvements in quality and service for the Model 3 and Model Y are earning positive feedback from these incentives, such aggressive strategies midway through the quarter may signal deeper challenges. Some experts feel the perks are end-of-quarter level incentives despite it only being about halfway through the quarter. While Tesla's U.S. sales are down, global EV sales continue to rise. The company has also benefited from being the sole automaker exempt from a major automotive tariff, thanks to meeting certain compliance criteria. Still, Tesla faces stiff competition from a growing roster of EV makers offering alternatives to consumers. Tesla owners can still tap into cost savings with EVs, including lower fuel costs, potential solar integration, and tax credits through the Inflation Reduction Act, though these incentives could be threatened by future policy changes. As the EV market evolves, Tesla's latest maneuvers highlight the pressure facing even industry leaders. Whether the discounts and perks will be enough to reverse the sales slump remains to be Pushes Hard with New Incentives as Sales Slip first appeared on Men's Journal on Jun 3, 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
